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cess could not be reproduced under cell-free conditions
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Adriano Aguzzi* and Magdalini Polymenidou
Institute of Neuropathology
University Hospital of Zu¨rich
infectious agent damages the brain, and the function ofSchmelzbergstr. 12
the normal protein continues to be obscure.CH-8091 Zu¨rich
The Timeline of TSE ResearchSwitzerland
In one or the other form, prions have captured a sizeable
mind share for almost two centuries (Table 1). Scrapie—
the prototypic prion disease affecting sheep and goat—Prions have been responsible for an entire century of
had been a concern since the 19th century. This is under-tragic episodes. Fifty years ago, kuru decimated the
standable given the importance of the wool textilepopulation of Papua New Guinea. Then, iatrogenic
business in the industrial revolution. But the crucialtransmission of prions caused more than 250 cases
breakthrough was already achieved in the 1930s by theof Creutzfeldt-Jakob disease. More recently, trans-
experimental transmission of scrapie to goats (Cuillemission of bovine spongiform encephalopathy to hu-
and Chelle, 1939). Little happened in the two followingmans caused a widespread health scare. On the other
decades, until Carleton Gajdusek showed that kuru,hand, the biology of prions represents a fascinating
which was decimating the aborigines of Papua Newand poorly understood phenomenon, which may ac-
Guinea (Gajdusek and Zigas, 1957), was a transmissiblecount for more than just diseases and may represent
spongiform encephalopathy. Interestingly, the first at-a fundamental mechanism of crosstalk between pro-
tempts at transmitting kuru to primates failed for theteins. The two decades since Stanley Prusiner’s for-
same reason that experimental transmission of scrapiemulation of the protein-only hypothesis have wit-
among sheep had failed for decades: the incubationnessed spectacular advances, and yet some of the
time of the disease was longer than the patience ofmost basic questions in prion science have re-
the investigators (Schwartz, 2003). Following a concisemained unanswered.
suggestion by William Hadlow that kuru resembled
scrapie, and hence might exhibit a very long incubationIntroduction
time (Hadlow, 1959), Gajdusek achieved transmissionA few years ago, it was memorably stated that prion
of kuru to chimps (Gajdusek et al., 1966, 1967) and,diseases (also termed transmissible spongiform encepha-
shortly thereafter, transmission of Creutzfeldt-Jakoblopathies, or TSE) constitute one of the best-understood
disease (CJD) (Gibbs et al., 1968).groups of neurodegenerative diseases (DeArmond and
It is remarkable (and somewhat sobering) to note thatPrusiner, 1995). Depending on whom you ask, this state-
some of the questions that had already been formulatedment may be regarded as entirely correct or completely
in the 19th century are still open. For example, is sheepoff the mark.
scrapie a predominantly genetic or infectious disease?Of course, prion diseases are quite well understood.
If the latter is true, how does it spread among flocks?Largely thanks to the enthusiasm and intuition of pio-
The wildfire-like epizootic of chronic wasting disease inneers such as Stanley Prusiner and Charles Weissmann,
North American cervids (Williams and Young, 1980), asprogress in prion science has experienced two decades
well as the “scrapie eradication plan” of the Europeanof quantum leaps. These include the isolation of the
Union (which aims at selective breeding of purportedlydisease-associated, protease-resistant prion protein,
scrapie-resistant sheep genotypes), bears the most re-
PrPSc (Bolton et al., 1982), the formulation of the protein-
cent witness to the general importance of these issues.
only hypothesis (Prusiner, 1982), the cloning of the Prnp
The Nature of the Prion
gene that encodes PrPC and the startling realization that Throughout this paper, the term “prion” is used to de-
it is a normal, cellular gene (Basler et al., 1986; Chesebro note the infectious principle active in TSEs. The various
et al., 1985; Oesch et al., 1985), the discovery that the hypotheses of TSE pathogenesis state that the prion
host-determined aspects of the “species barrier” are may be congruent, partially overlapping, or different
crucially governed by the sequence of PrPC (Scott et from the protease-resistant form of PrP found in prion
al., 1989), the linkage between PRNP mutations and diseases, which is termed PrPSc.
hereditary prion disease (Hsiao et al., 1989), and the Two papers reprinted in the current issue of Cell repre-
demonstration that PrPC-deficient mice are alive and sent two major turning points in prion research. The first
well, but resistant to prion diseases (Bu¨eler et al., paper describes the discovery, by Stanley Prusiner and
1992, 1993). coworkers, of a crucial property of the prion: its remark-
And yet one may argue that prions are not well under- able resilience against proteolytic degradation (McKin-
stood at all! We are still unable to precisely pinpoint the ley et al., 1983). Digestion with 50 g/ml of proteinase
physical nature of the agent (Chesebro, 1998), and we K (PK) at 37C for 2 hr would not degrade the carboxy-
do not avail of any high-resolution molecular structure proximal domain of PrPSc nor decrease the infectious
of PrPSc. Hence, the models of conversion of PrPC to titer of the prion preparation. But PrPSc is not “unbreak-
PrPSc are speculative at best, and the conversion pro- able” and can eventually be digested by more vigorous
enzymatic treatment—in which case prion infectivity ti-
ters will also subside. This remarkable discovery identi-*Correspondence: adriano@pathol.unizh.ch
Cell
314
Table 1. Essential Chronology of Prion Research
Mid 18th Century Earliest Description of Scrapie Recorded
1898 Neuronal vacuolation discovered in brains of scrapie-sick sheep
1918 Contagious spread of scrapie in natural conditions suspected
1920 First cases of CJD described (Creutzfeldt, 1920; Jakob, 1921)
1937 Scrapie epidemic in Scotland following administration of formalin-treated louping ill vaccine prepared from sheep
brain
1939 Experimental transmission of scrapie reported (Cuille and Chelle, 1939)
1955–1957 Kuru discovered among Fore people of Papua New Guinea (Gajdusek and Zigas, 1957)
1959 Similarities between kuru and scrapie noted (Hadlow, 1959)
1961 Multiple strains of scrapie agent described (Pattison and Millson, 1961)
1961 Scrapie transmitted to mice (Chandler, 1961)
1963 Transmission of kuru to chimpanzees reported (Gajdusek et al., 1966)
1966 Scrapie agent found to be highly resistant to ionizing radiation and ultraviolet light (Alper et al., 1966, 1967)
1967 First enunciation of the protein-only hypothesis (Griffith, 1967)
1968 CJD transmitted to chimpanzees (Gibbs et al., 1968)
Description of Sinc gene affecting scrapie incubation period in mice (Dickinson et al., 1968)
1974 First documented iatrogenic prion transmission (corneal graft) (Duffy et al., 1974)
1980 Protease resistant, highly hydrophobic protein discovered in hamster brain fractions highly enriched for scrapie
infectivity (Prusiner et al., 1980)
1982 Prion concept enunciated (Prusiner, 1982)
1985 Gene encoding PrPC cloned (Chesebro et al., 1985; Oesch et al., 1985)
1986 PrPC and PrPSc isoforms shown to be encoded by same host gene (Basler et al., 1986)
1987 Linkage between Prnp and scrapie incubation period in mice (Westaway et al., 1987)
First report of BSE in cattle (Wells et al., 1987)
1989 Mutation in PrP linked to Gerstmann-Stra¨ussler syndrome (Hsiao et al., 1989)
Importance of isologous PrPC/PrPSc interactions established (Scott et al., 1989)
1992 Ablation of Prnp by gene targeting in mice (Bu¨eler et al., 1992)
1993 Prnpo/o mice are resistant to scrapie inoculation (Bu¨eler et al., 1993; Sailer et al., 1994)
Structural differences between PrPC and PrPSc isoforms noted (Pan et al., 1993)
1994 Cell-free conversion of PrPC to protease-resistant PrP (Kocisko et al., 1994)
1996 New variant of CJD identified (Will et al., 1996)
BSE prion strain carries a distinct glycotype signature (Collinge et al., 1996)
First NMR structure of core murine PrPC solved (Riek et al., 1996)
1997 Evidence that nvCJD is caused by the BSE agent (Bruce et al., 1997; Hill et al., 1997a)
B lymphocytes necessary for peripheral prion pathogenesis (Klein et al., 1997)
1998 Genes controlling incubation period are congruent with Prnp (Moore et al., 1998)
1999 Discovery of the PrPC homolog (Moore et al., 1999)
2000 Temporary depletion of lymphoid FDCs impairs prion replication (Montrasio et al., 2000)
Experimental transmission of BSE in sheep by blood transfusion (Houston et al., 2000)
2001 Complement involved in prion pathogenesis (Klein et al., 2001; Mabbott et al., 2001)
2003 Transgenic expression of soluble PrP inhibits prion replication (Meier et al., 2003)
fied PrPSc as the first reliable surrogate marker of prion 2003). The excitement in Zurich was considerable as it
became gradually clear that inoculation of Prnpo/o miceinfection. The impact of this technology was phenome-
nal: even now, twenty years after its original description, with brain homogenate from scrapie-sick mice failed to
induce disease of any kind (Bu¨eler et al., 1993) or elicitthe detection of PK-resistant prion protein (termed
PrP27-30 because of its molecular weight after hydrolysis any subclinical replication of the agent (Sailer et al.,
1994).of its PK-sensitive amino-terminal domain) remains the
gold standard for biochemical diagnosis of prion dis- The study of Bu¨eler and colleagues has sometimes
been invoked as the “final proof” of the protein-onlyeases and forms the basis for all of the currently mar-
keted BSE tests (Figure 1). hypothesis. That is certainly not the case: the knockout
experiment was designed to disprove Prusiner’s hypoth-The second paper, to which one of us had the privilege
of contributing, verifies a crucial prediction of Prusiner’s esis—and it would have certainly done so if Prnpo/o mice
had developed disease. As always with negative results,protein-only hypothesis (Bu¨eler et al., 1993). If PrPSc mul-
tiplies by imparting its conformation onto host-borne alternative interpretations can be offered (Popper, 1991).
Those skeptical of the prion hypothesis were quick inPrPC, organisms devoid of PrPC should be resistant to
prion infection. This idea was compelling, but in the early pointing out that PrPC may be a receptor for a hitherto
unidentified virus, whose ablation would confer antiviraldays of prion research, no technology was available that
would allow for the targeted removal of a specific gene resistance. Yet it is fair to say that the resistance to
scrapie of Prnp knockout mice constitutes one of thefrom the mammalian genome. As soon as in vivo gene
ablation became feasible (Zijlstra et al., 1990), Hansru¨edi most stringent challenges to the protein-only hypothe-
sis. Hence its failure is very significant.Bu¨eler and Charles Weissmann set out to ablate the
Prnp gene, which encodes PrPC. Prnpo/o mice were alive The availability of Prnpo/o mice has triggered a cascade
of technological and conceptual advances. For exam-and well (Bu¨eler et al., 1992), nowithstanding some mi-
nor abnormalities (Collinge et al., 1994; Tobler et al., ple, it emerged that PrPC, besides controlling prion repli-
cation, is necessary for neuronal damage: Prnpo/o neu-1996; Watarai et al., 2003)—some of which may not even
be causally related to the prion gene (Aguzzi and Hardt, rons adjacent to infected Prnp/ brain grafts do not
Review
315
Figure 1. Diagnostic Procedures for Prion Diseases
Synopsis of current diagnostic methods for TSE in humans (left panel) and in experimental animals (right panel). Most methods rely upon the
detection of PK-resistant PrPSc. The tissues in which PrPSc has been detected in humans are listed in the middle panel. While PrPSc deposits
are most abundant in the CNS, the list of peripheral organs in which PrPSc can be detected has significantly grown in recent years; it now
includes most lymphoid organs as well as skeletal muscle.
incur damage (Brandner et al., 1996a). PrPC is also in- bodies discriminating between PrPC and PrPSc. This is
surprising in view of the dramatic structural differencesvolved in the transport of the infectious agent from pe-
ripheral sites to the central nervous system: its expres- between these two isoforms and their differential bind-
ing to serum proteins (Fischer et al., 2000). Does thesion appears to be needed in a sessile compartment
(Bla¨ttler et al., 1997), which is likely to be congruent failure of the immune system to generate antibodies
specific for PrPSc indicate that all relevant neoepitopeswith stromal components of the lymphoreticular tissue
(Montrasio et al., 2000) and of the peripheral nervous of PrPSc that are newly exposed by the conversion of the
protein to its disease-associated state are inaccessible?system (Glatzel et al., 2001). The microenvironment of
lymphoid organs appears to control the velocity of neu- Early claims of discriminatory antibodies, such as Prio-
nics’ 15B3 clone (Korth et al., 1997), have not lived uproinvasion (Prinz et al., 2003a).
PrPC is not only produced by neurons; its expression is to the expectations. A recently developed antibody
against a characteristic tripeptide (YYR) exposed inin fact quite ubiquitous, notably including lymphocytes
(Cashman et al., 1990) and stromal cells of lymphoid PrPSc, but not in PrPC, may be more promising (Paramith-
iotis et al., 2003). However, the YYR motif is certainlyorgans (Kitamoto et al., 1991). As a result, wild-type
mice enjoy an extremely tight immunological tolerance not specific to PrPSc, and the usefulness of this antibody
awaits independent confirmation.against PrPC, which had rendered the production of
high-affinity immunoreagents very difficult. Instead, the The Spontaneous Generation of Prions
A mesmerizing implication of the protein-only hypothe-immunization of Prnpo/o mice yielded large numbers of
very high-affinity antibodies, some of which form the sis is the propagation of prions in an entirely synthetic
system. If the infectious agent is a misfolded form ofbasis for the current crop of BSE tests.
Still, it proved difficult to generate conformational anti- PrP, and its replication is promoted by its interaction
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with PrPC, then the entire process should be, in principle, Form Follows Function
reproducible in a cell-free environment consisting exclu- If the protein-only hypothesis is correct, one could argue
sively of PrPC, PrPSc, and maybe some “promoting fac- that the prion problem is, in essence, one of protein
tors.” The importance of such an experiment is immedi- structure. Whether prions multiply by template-directed
ately evident: de novo generation or amplification of refolding or by seeded nucleation, certain domains of
prions from defined components would prove the pro- PrPC (or the entire protein) would need to rearrange
tein-only hypothesis and set to rest all other alternative such that the monomeric protein becomes capable of
explanations (Aguzzi and Weissmann, 1997). Besides, inducing the same change in further PrPC monomers
such a system would be extremely valuable for studying (Figure 2A). This idea represents the core of the “tem-
the conversion process, for exploring the species barrier plate-directed refolding” hypothesis, which predicates
phenomenon, and for testing conversion antagonists an instructionist role for PrPSc onto PrPC. The experimen-
that may provide therapeutic compounds. tal evidence is compatible with this hypothesis, yet no
A decisive milestone toward this goal was accom- positive evidence in its favor has come forward.
plished with the establishment of an in vitro conversion Alternatively, it has been proposed that PrPSc exists
system based on the coincubation of substantially puri- in a mass-action equilibrium with PrPC. Such equilibrium
fied constituents (Kocisko et al., 1994). This seminal would be heavily shifted toward the side of PrPC so that
work showed that incubation of radiolabeled PrPC with only minute amounts of PrPSc would coexist with PrPC.
cold PrPSc leads to the formation of PK-resistant radio- If that were the case, PrPSc could not possibly represent
labeled PrP—indicating that PrPSc had somehow im- the infectious agent since it would be ubiquitous. Ac-
parted some of its properties onto PrPC. The original cording to this “nucleation” hypothesis (Jarrett and
system required vastly superstochiometric amounts of Lansbury, 1993), however, the infectious agent would
PrPSc, which precluded the detection of any increase in consist of a highly ordered aggregate of PrPSc mole-
prion infectivity. However, the method was used to cules. The aggregated state would be an intrinsic prop-
probe the conversion efficiency between PrP molecules erty of infectivity: monomeric PrPSc would be harmless,
with different primary sequences and thereby, to some but it might be prone to incorporation into nascent PrPSc
extent, the tightness of species barriers (Bessen et al., aggregates (Figure 2B).
1995; Horiuchi et al., 2000). In the intervening years, the Testing these hypotheses requires precise knowledge
in vitro conversion methodology has yielded remarkable of the structural features of both PrPC and PrPSc. To
insights and even assays for identification of antiprion date, such knowledge has not progressed to a state
compounds. that would allow for resolution of this question. The
It was reported that PrPSc could be amplified by cycles structure of PrPC has been studied extensively with high-
of sonication followed by incubation with brain homoge- resolution methods. Both crystallography (Knaus et al.,
nate (Saborio et al., 2001). The idea behind this experi- 2001) and nuclear magnetic resonance (NMR) spectros-
ment was that sonication might fracture large PrPSc ag- copy (Riek et al., 1996) have yielded detailed insights
gregates into smaller units, each one of which would into the arrangement of PrPC at the atomic level. PrPSc,
accrue PrPC and act as independent “infectious unit.” however, has been amenable merely to low-resolution
Several skeptics, however, have pointed out that this structural methods.
intriguing report is still awaiting independent confirma- The NMR studies of recombinant PrPC yielded a big
tion. Also, more than two years after its publication, no surprise. The amino-proximal half of the molecule is not
evidence has come forward that this “protein misfolding structured at all, whereas the carboxy-proximal half is
cyclic amplification” would augment the infectivity of globular and contains three  helices (Riek et al., 1996,
any given sample. 1997). This does not mean that the amino terminus must
Along parallel lines, conditions were established at be randomly coiled in vivo: functional studies in trans-
that recombinantly produced PrP was transformed into
genic mice imply that the domain comprising amino
an isoform termed PrP, with several typical properties
acids 32-121 carries out important physiological func-
of PrPSc (Jackson et al., 1999): increased sheet content,
tions (Shmerling et al., 1998). Maybe the flexible tail ofaggregability, and resistance to PK. This molecule was
PrPC acquires a defined structure once it reaches itsdeemed quite interesting for two main reasons. Firstly,
natural habitat on rafts, which are specialized micro-one had hoped that immunization of mice with PrP
domains of the plasma membrane (Naslavsky et al.,might give rise to conformation-specific monoclonal an-
1997).tibodies, which would help in discriminating directly be-
Why wasn’t it yet possible to elucidate the structuretween PrPC and PrPSc. The latter would render obsolete
of PrPSc? As discussed above, prion infectivity can bethe venerable PK digestion assay and may facilitate the
recovered only from prion-infected mammalian organ-development of higher-throughput PrPSc immunoassays.
isms or (in much lesser quantities) from infected culturedSecondly, PrP might be equivalent to PrP* (Weiss-
cells. In neither case is the purity of the recovered mate-mann, 1991), a metastable intermediate postulated to
rial satisfactory. Moreover, infectivity-associated PrPScarise during conversion of PrPC to PrPSc. If so, inoculation
appears to consist obligatorily of aggregates; disaggre-of mice with suitable amounts of PrP might result in
gation sterilizes prions (Prusiner et al., 1981). But insolu-the generation of transmissible disease.
ble aggregates are resilient to most technologies forAt present PrP has yet to fulfill either of these two
determination of protein structure; hence all we knowexpectations. Yet it is not implausible that additional
is that PrPSc consists mainly of-pleated sheet (Caugheyexperimentation in specifically devised animal models
et al., 1991) and that PrPSc aggregates expose a remark-may change this negative outcome. As with transmis-
sion of kuru to chimps, it is advisable to be patient. ably ordered structure (Wille et al., 2002).
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Figure 2. Models for the Conformational Conversion of PrPC into PrPSc
(A) The “refolding” or template assistance model postulates an interaction between exogenously introduced PrPSc and endogenous PrPC,
which is induced to transform itself into further PrPSc. A high energy barrier may prevent spontaneous conversion of PrPC into PrPSc.
(B) The “seeding” or nucleation-polymerization model proposes that PrPC and PrPSc are in a reversible thermodynamic equilibrium. Only if
several monomeric PrPSc molecules are mounted into a highly ordered seed, further monomeric PrPSc can be recruited and eventually aggregates
to amyloid. Within such a crystal-like seed, PrPSc becomes stabilized. Fragmentation of PrPSc aggregates increases the number of nuclei,
which can recruit further PrPSc and thus results in apparent replication of the agent.
Yeast Prions BSE and Other Prion Threats to Humans
When Stanley Prusiner started his first attempts at tack-Thirty years ago, Francois Lacroute described mysteri-
ling the problem of TSE (Prusiner et al., 1977), this groupous yeast traits that apparently propagated by nonmen-
of diseases was not exactly in the public limelight. How-delian genetics (Lacroute, 1971). For two decades, this
ever, bovine spongiform encephalopathy (BSE) was rec-phenomenon remained unexplained—until Reed Wick-
ognized a few years later (Wells et al., 1987) —an eventner proposed that the unusual genetic properties of
that would dramatically change the public perceptionthese mutants could be explained by a prion-like behav-
of prion diseases. CJD was, and fortunately continuesior of two previously identified yeast proteins: Sup35p,
to be, exceedingly rare: its incidence is typically 1/106an essential component of the translation termination
inhabitants/year, but reaches 3/106 inhabitants/year inmachinery, and Ure2p, a protein that regulates nitrogen
Switzerland, which is currently reporting the highestmetabolism (Wickner, 1994). Further yeast prions were
number of cases (Glatzel et al., 2002, 2003b). Kuru, onceidentified in the following, so that one could now argue
decimating the population of Papua New Guinea, hasthat the yeast prion phenomenon is much better under-
almost disappeared. Iatrogenic transmission of CJD hasstood than its mammalian counterpart. The prion-form-
principally occurred through improperly sterilized neu-ing domain (PrD) of Sup35p is modular and transferable;
rosurgical instruments, transplants of dura mater, andartificial prions were generated by fusing a mammalian
administration of pituitary hormones of cadaveric origin.
receptor to the Sup35p PrD (Li and Lindquist, 2000).
While the two latter routes of transmission no longer
In the prion-infected state (termed ), Sup35p is se- pose a major threat, a significant number of individuals
questered into fibrils. As consequence, termination of may have been infected during a critical time window
translation is impaired, and reading frames situated and may develop CJD in the coming years.
downstream of nonsense codons can be translated into Variant CJD (vCJD) has caused some 140 deaths in
proteins (Figure 3). Just like in street traffic, ignoring stop the United Kingdom and a few cases in France, Italy,
signs does not generally constitute healthy behavior, and Canada (http://www.doh.gov.uk/cjd/stats/aug02.
but Susan Lindquist made a convincing case that such htm). Epidemiological, biochemical, and histological evi-
transgressions may play a decisive role in creating “evo- dence suggests that vCJD represents transmission of
lutionary buffers.” By occasionally switching on bicis- bovine spongiform encephalopathy (BSE) prions to hu-
tronic reading frames through the  state, yeast cells mans (Aguzzi, 1996; Aguzzi and Weissmann, 1996;
can reversibly probe the effects of combinatorial expres- Bruce et al., 1997; Hill et al., 1997a). The incidence of
sion of mutated genes, hence creating additional layers vCJD in the United Kingdom rose each year from 1996
to 2001, evoking fears of a large upcoming epidemic.of evolutionary variation (True and Lindquist, 2000).
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Figure 3. Function of the Yeast Prion, Sup35
(A) Sup35 consists of an amino-terminal glu-
tamine-rich module crucial for conversion
into the prion state.
(B) In the  state, Sup35 is required for reli-
able termination of translation.
(C) In  yeast cells, however, Sup35 is se-
questered in ordered fibrillary aggregates.
Shortage of functional Sup35 leads to trans-
gressions in stop codon recognition and
translation of downstream reading frames
(red line). In the off state, such pseudogenes
may accumulate otherwise toxic mutations.
Acquisition of the on () state may lead to
the appearance of new phenotypes, hence
increasing the complexity of genetic vari-
ability.
Since the year 2001, however, the incidence of vCJD in function of the cellular prion protein is still unknown. A
number of subtle abnormalities have been described inthe UK appears to be stabilizing (http://www.cjd.ed.ac.
PrP-deficient mice (Collinge et al., 1994; Tobler et al.,uk/vcjdq.htm). One may argue that it is too early to draw
1996), but their molecular basis is undefined, and thereany far-reaching conclusions, but each year passing
may be some variability due to the genetic backgroundwithout any dramatic rise in the number of cases in-
of the mice utilized. Hence, the only definite phenotypecreases the hope that the total number of vCJD victims
of Prnpo/o mice is their resistance to prion inoculationwill be limited (Valleron et al., 2001). Presently, there is
(Bu¨eler et al., 1993) —yet it seems unlikely that a singularreason to hope that the incidence of vCJD in the United
protein that is as highly conserved among species asKingdom may already be subsiding (Andrews et al.,
PrPC, from turtles to frogs, fish, and humans, has evolved2003).
for the sole reason of bestowing susceptibility tovCJD prions accumulate prominently in lymphoreticu-
prion diseases.lar tissue, and the latter can be used for diagnostic
If the function of PrPC were completely unrelated topurposes. Surprisingly, prions accumulate in lymphoid
prion disease pathogenesis, one might argue that PrPCorgans and muscle of sporadic CJD patients (Glatzel et
is just one of many thousands proteins whose functional., 2003a).
awaits clarification—but why should then the elucidationThere is uncertainty surrounding the danger of trans-
of the function of PrPC be given any priority? On themission to humans represented by chronic wasting dis-
other hand, the function of PrPC may very well haveease. In fact, even transmissibility of BSE to humans
something to do, in a subtle way, with prion-inducedrelies on circumstantial evidence. Epidemiology and
damage. Prnp ablation does not elicit disease, evenbiochemistry favor the link between BSE and vCJD, but
when induced postnatally (Mallucci et al., 2002); henceare not ultimately conclusive. The Koch postulates
prion pathology is unlikely to come about by loss of
(which would unambiguously assign an infectious agent
PrPC function. But assume that PrPC transduces a signal,
to a disease) have never been fulfilled, and experimental or that it possesses some enzymatic activity. If so, con-
inoculation of humans was fortunately never performed. version to PrPSc may alter signal transduction strength,
Also, accidental exposure to BSE infectivity of a sizable or substrate specificity, thereby conferring a toxic domi-
collective at a precisely defined time point has never nant function. In these scenarios, understanding the
occurred, or did not result in disease. Likewise, we do function of PrPC may help in deciphering prion pathology
not know whether scrapie is just a veterinarian problem and maybe even devising therapeutical approaches.
that affects only sheep and goat or whether it can cross So, what is the evidence that PrPC may be a signal
species barriers and affect humans. Finally, it is un- transducer or an enzyme? Speculations on both hypoth-
known whether BSE, upon transmission to sheep, re- eses abound, but facts are scarce. Crosslinking PrPC
mains as dangerous for humans as cow-derived BSE, with F(ab)2 antibody fragments has been reported to
or whether it becomes attenuated and acquires the (al- activate intracellular tyrosine kinases (Mouillet-Richard
legedly) innocuous properties of bona fide sheep et al., 2000). However, this phenomenon was not re-
scrapie. ported to occur in vivo, and the only cell line in which it
was described was never made available to the scientific
The Elusive Function of PrPC community for independent verification. This does not
In spite of the fact that the first Prnp knockout mice are exclude that PrPC functions as a signal transducer, but
the present case is of limited strength.available since 12 years (Bu¨eler et al., 1992), the normal
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Is PrPC an enzyme? Glockshuber noted that PrPC has mice abolishes the Purkinje cell degeneration pheno-
similarities to membrane-anchored signal peptidases type (Nicolas Genoud, Axel Behrens, and A.A., unpub-
(Glockshuber et al., 1998), but his observation has not lished data).
been substantiated by functional data. The speculation Most intriguingly, Dpl-dependent neurodegeneration
that PrPC may be a superoxide dismutase (Brown et al., is abolished by cell-autonomous coexpression of full-
1997, 1999) was perceived as particularly attractive in length PrP (Rossi et al., 2001). Formally, this indicates
view of its multiple copper binding sites, and it was recently that Dpl and PrPC act antagonistically, maybe because
suggested that amino-proximally truncated PrPC may de- they bind to a hitherto conjectural common ligand (Fig-
press endogenous dismutase activity (Sakudo et al., ure 4A), which was provisionally termed LPrP (Shmerling
2003). However, PrPC does not make any measurable et al., 1998). Alternatively, PrPC and Dpl might engage
contribution to dismutase activity in vivo (Hutter et al., in heterooligomeric complexes (Figure 4B), whose func-
2003; Waggoner et al., 2000). tion could depend on their stoichiometric composition
Maybe PrPC and PrPSc do not possess any intrinsic (Behrens and Aguzzi, 2002). The same mechanism may
biological activity, yet they modify the function of other be operative in transgenic mice produced by Doron
proteins. This supposition has prompted a search for Shmerling and Charles Weissmann (Shmerling et al.,
PrP-interacting partners, and there is no dearth of PrP 1998) in an attempt to specify the domain of PrPC re-
binding proteins: the antiapoptotic protein Bcl-2 (Kurschner quired for prion replication. Expression of a PrP variant
et al., 1995), caveolin (Gorodinsky and Harris, 1995; Har- that lacks a large part of the N terminus of PrP in Prnpo/o
mey et al., 1995), the laminin receptor precursor (Rieger mice induces spontaneous cerebellar degeneration,
et al., 1997), plasminogen (Fischer et al., 2000), and which however affects granule cells rather than Purkinje
N-CAM (Schmitt-Ulms et al., 2001). None of these inter- cells (the promoter used was inactive in Purkinje cells)
actors, however, have yet revealed a functional pathway and can also be prevented by the coexpression of a
in which PrPC would be involved in vivo. It was recently single endogenous Prnp allele. Structural studies have
shown that PrP-deficient macrophages do not support shown that human Dpl contains a relatively short, flexibly
bacterial “swimming internalization” of the Gram-nega- disordered “tail” comprising residues 24-51 and a globu-
tive bacterium, Brucella abortus (Watarai et al., 2003), lar domain extending from residues 52 to 149 for which
and that PrPC interacts with a Brucella heat shock pro- a detailed structure was obtained (Luhrs et al., 2003).
tein, Hsp60. These findings raise the question of whether Despite their highly divergent primary sequence, Dpl
PrPC may participate in a general Hsp60-dependent is largely superimposable to the carboxy-proximal half
“danger sensing” mechanism (Aguzzi and Hardt, 2003). of PrPC.
A Doppelganger of the Prion Protein The molecular pathways by which Dpl and amino-
The original Prnpo/o mice did not display any severe proximally truncated PrP damage the cerebellum are
abnormalities. However, some of the knockout lines unknown. However, the suppressibility of both pheno-
generated later, i.e., Ngsk Prnp/ (Sakaguchi et al., types by full-length PrPC is indicative of a high degree
1996), ZH-II Prnp/ (Rossi et al., 2001), and Rcm0 mice of specificity. Therefore, we contend that this model
(Moore et al., 1999), develop progressive cerebellar Pur- presently represents the best validated window of entry
kinje cell degeneration with ataxia in advanced age. This to determine the function of PrPC in vivo.
phenotype was originally attributed to the lack of PrPC
and ran counter to the two PrP knockout mouse lines
The Basis of Prion Neurotoxicityproduced earlier: the ZH-I Prnpo/o (Bu¨eler et al., 1992)
PrPSc accumulation in the brain is the hallmark of prionand the Edbg Prnp/ mice (Manson et al., 1994). The
diseases, and PrPSc is—for all we know—a major compo-characterization of Ngsk Prnp/ mice was particularly
nent of the infectious agent. But is PrPSc also directlyconscientious: the authors reintroduced Prnp as a trans-
responsible for the devastating CNS pathology typicalgene by genetic crosses and showed that this manipula-
of prion diseases? On the one hand, accumulation oftion rescued the Purkinje cell degeneration. It seemed
amyloid (or preamyloid) in the CNS is likely to be gener-entirely reasonable, hence, to conclude that PrPC is nec-
ally unhealthy, as exemplified by Alzheimer’s diseaseessary for cerebellar homeostasis. Yet this interpretation
(Aguzzi and Haass, 2003) and cerebral vascular amy-could not be easily reconciled with the lack of phenotype
loidoses (Revesz et al., 2002). On the other hand, chronicin the remaining knockout lines and eventually was
deposition of PrPSc does not damage Prnp knockoutproven to be incorrect.
brains (Brandner et al., 1996a), and depletion of PrPCThe inconsistency was eventually resolved by David
from neurons of scrapie-infected mice prevents diseaseWestaway’s discovery of a novel gene located just 16
(Mallucci et al., 2003). Therefore, accumulation of PrPSckilobases downstream of Prnp and encoding a 179 resi-
is unlikely to fully account for prion pathology. If so,due protein that has sequence similarities to the C termi-
what is it that actually kills the neurons?nus of PrP and was thus termed Doppel or Dpl (Moore
Brains of Creutzfeldt-Jakob disease victims look trulyet al., 1999). It then emerged that the gene targeting
frightening. In heavily affected areas, there is hardly anystrategy in all ataxic PrP-deficient mice was associated
neuron left, and the brain tissue texture is coarsenedwith deletion of a splice acceptor site located on the
by the abnormal growth of astrocytes (“gliosis”) andcoding exon of Prnp. This modification effectively places
microglial cells. The most telling hallmark is spongiosis,Dpl under transcriptional control of the Prnp promoter.
a peculiar microvacuolation affecting residual neuralAs a consequence, brain expression of Dpl, which is
cells.normally very low, skyrockets in Nsgk, ZH-II, and Rcm0
The molecular steps that emanate from prion replica-mice (Weissmann and Aguzzi, 1999). This is clearly neu-
rotoxic, as ablation of the Dpl reading frame from ZH-II tion and lead to such destruction are unknown. Some
Cell
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Figure 4. Hypothetical Models for the Function of PrPC and the Neurotoxicity of PrPC and Dpl
(A) PrPC and Dpl (or PrP) may compete for a common ligand, provisionally termed LPrP. In order to accommodate the lack of neurodegeneration
in Prnpo/o mice, however, one would have to postulate the existence of a functional PrPC analog, here termed 	. While this model accommodates
all experimental findings known to date, no physical evidence has come forward for the existence of LPrP and 	.
(B) Dpl and PrP may form a homomultimeric toxic aggregate, which may be inactivated by participation of full-length PrPC. Toxicity may
come about by various hypothetical mechanisms. For example, if such aggregates were to span a membrane, toxic properties may relate to
the formation of pores.
gain of toxic function is likely, as constitutive or postna- most antiprion compounds were identified in cell culture
assays, where chronically prion-infected neuroblastomatal depletion of PrPC does not trigger any pathology. A
lively discussion is developing on the role of abnormal cells are “cured” of their PrPSc and prion burden. A star-
tling variety of substances appears to possess suchPrPC topologies. Targeting of PrP to the cytosol results
in rapidly lethal neurodegeneration (yet without PrPSc), prion-curing properties; a nonexhaustive list includes
compounds as diverse as Congo red (Caughey andand proteasome inhibition induces a slightly protease-
resistant PrP species in cultured cells, which may be Race, 1992), amphotericin B, anthracyclins (Tagliavini et
al., 1997), sulfated polyanions (Caughey and Raymond,self-sustaining—at least for a while (Ma and Lindquist,
2002; Ma et al., 2002). Therefore, prion toxicity may start 1993), porphyrins (Priola et al., 2000), branched poly-
amines (Supattapone et al., 2001), “ sheet breakers”with retrotranslocation of PrPC from the endoplasmic
reticulum to the cytosol, in conjunction with impaired (Soto et al., 2000), and the spice curcumin (Caughey et
al., 2003).proteasomal function. While PrP is clearly toxic in the
cytosol, the details of how it may get there are debated. Disappointingly, none of these compounds proved
very effective for actual therapy of sick animals—letCytosolic PrP retains its secretory leader peptide and
does not contain a glycosyl phosphatidyl inositol an- alone patients. We therefore believe that it is premature
to treat patients with alleged antiprion drugs on the solechor, suggesting that it never enters the endoplasmic
reticulum (Drisaldi et al., 2003). Whether toxicity of cyto- basis of antiprion efficacy in neuroblastoma cells. This
shortcut was taken in the case of quinacrine, whichsolic PrP is universal, however, is currently quite hotly
discussed (Roucou et al., 2003). On the other hand, cures scrapie-infected cultured cells with impressive
efficacy (Korth et al., 2001), yet appears to be utterlyLingappa found that PrPC assumes a transmembrane
topology (CtmPrP), whose concentration correlates with ineffective in scrapie-infected mice (Collins et al., 2002)
and in CJD patients (Cooper, 2002), besides being se-neurotoxicity (Hegde et al., 1998, 1999). These data sug-
gest that CtmPrP represents a major toxic moiety. verely hepatotoxic (Scoazec et al., 2003).
We still know nothing of the biochemical pathways Why do scrapie-infected cells fare so poorly as a
leading to brain damage, be they triggered by cyto- model system for prion therapy? In our experience, in-
plasmic PrP or by CtmPrP; these may lead to the identifi- fection rarely hits all cells in any given culture, and the
cation of therapeutic targets and may share components prion-infected state can be quite unstable. Therefore,
with other neurodegenerative diseases. one could speculate that a variety of stressors may mas-
querade as antiprion cures by conferring a selective
advantage to noninfected cells. This interpretationThe Future of Prion Therapeutics
would explain the puzzling observation that antiprionAn impressive wealth of molecules was touted as poten-
“cure” is brought about by compounds with no structuraltial antiprion lead compounds. However, none of these
or biological similarities.therapeutical leads have proven their usefulness yet in
Cytidyl-guanyl oligodeoxynucleotides (CpG-ODN), whichclinical settings, and some have conspicuously failed.
One of the possible problems derives from the fact that bind Toll-like receptor 9 (TLR9) and stimulate innate
Review
321
immune responses, were reported to delay disease however, are enormous. While providing an encouraging
upon chronic administration to scrapie-infected mice proof of principle, transgenic immunization cannot eas-
(Sethi et al., 2002). The contention that immune stimula- ily be reduced to practice. Further, no protection was
tion might protect against prions is extraordinary and is observed if treatment was started after the onset of
difficult to reconcile with the observation that immune clinical symptoms, suggesting that passive immuniza-
deficiencies of all kinds inhibit prion spread (Frigg et al., tion might be a good candidate for prophylaxis rather
1999; Klein et al., 1997, 1998, 2001; Prinz et al., 2003c). than therapy of TSEs. Active immunization, like in most
Besides, MyD88/ mice undergo normal prion patho- antiviral vaccines, may be more effective, but is ren-
genesis despite abrogation of TLR9 signaling (Prinz et dered exceedingly difficult by the stringent tolerance to
al., 2003b), and we could not evidence any major effects PrPC (Souan et al., 2001; F. Heppner, E. Pellicioli, M.P.,
of TLR9 stimulation on the course of disease—in a para- and A.A., unpublished results; and Figure 5B).
digm identical to that described originally (M.P., M. Soluble Prion Antagonists
Heikenwa¨lder, and A.A., unpublished data). Instead, re- In several paradigms, expression of two PrPC moieties
peated CpG-ODN administration proved extremely lym- subtly different from each other antagonizes prion repli-
photoxic (Heikenwalder et al., 2004)—a fact that may cation. For example, humans heterozygous for a com-
well explain its antiprion properties. mon Prnp polymorphism at codon 129 are largely pro-
On a more positive note, the tremendous interest in tected from CJD: this effect is so important that it may
this field has attracted researchers from various neigh- have acted as selective evolutionary pressure (Mead et
boring disciplines, including immunology, genetics, and al., 2003). Similarly, transgenic expression of hamster
pharmacology, and therefore it is to hope that rational PrPC renders Prnpo/o mice highly susceptible to hamster
and efficient methods for managing prion infections will prions, whereas coexpression of mouse PrPC diminishes
be developed in the future. this effect. Transdominant single nucleotide mutations
Immunotherapy against Prions? of Prnp have also been described (Perrier et al., 2002).
Prions are sturdy and their resistance against steriliza- The molecular basis for these effects is unknown;
tion is proverbial, yet exposure in vitro to anti-PrP anti- perhaps the subtly modified PrPC acts as a decoy by
sera can reduce the titer of infectious hamster brain binding incoming PrPSc (or protein X) and sequestering
homogenates (Gabizon et al., 1988). Anti-PrP antibodies it into a complex incapable of further replication.
were found to inhibit formation of protease-resistant PrP We tested the latter hypothesis by fusing an immuno-
in a cell-free system (Horiuchi and Caughey, 1999). Also, globulin Fc
 domain to PrPC. The Fc
 tail served multiple
antibodies (Klein et al., 2001) and F(ab) fragments to PrP purposes: (1) ligand dimerization, which may enhance
(Enari et al., 2001; Peretz et al., 2001) can suppress prion its avidity for interacting partners; (2) provision of a con-
replication in cultured cells. venient tag for affinity purification; (3) expression of the
While these data suggest the feasibility of antiprion protein as a soluble moiety, which allows for testing
immunoprophylaxis, the mammalian immune system is cell-autonomous effects; and (4) increased stability in
essentially tolerant to PrPC; this is hardly a surprise, body fluids. Excitingly, the PrP-Fc2 fusion protein was
given that PrPC is expressed on T and B cells. Ablation found to compete with PrPC for PrPSc (Figure 6) and
of Prnp (Bu¨eler et al., 1992) renders mice highly suscepti- to prolong the latency period of prion infection upon
ble to immunization with prions (Brandner et al., 1996b), expression in transgenic mice (Meier et al., 2003). It will
and indeed some of the best monoclonal antibodies to be exciting to determine whether PrP-Fc2 can act cell-
PrPC were generated in Prnpo/o mice (Prusiner et al., autonomously when delivered as a drug. If that proves
1993). true, soluble prion protein mutants may represent useful
Tolerance was circumvented by transgenic expres- prionostatic compounds.
sion of an immunoglobulin  chain containing the epi-
tope-interacting region of 6H4, a high-affinity anti-PrP
Prion Diagnosis: Weaknesses and Challengesmonoclonal antibody (Korth et al., 1997). The transgenic
Like in any other disease, early diagnosis would signifi- chain associated with endogenous  and  chains,
cantly advance the chances of success of any possiblesome pairings lead to reactive moieties and, conse-
interventional approach. But when compared to otherquently, to high anti-PrPC titers in Prnpo/o and Prnp/
fields of microbiological diagnostics, the tools for prionmice. The buildup of anti-PrPC titers, however, was more
diagnosis appear to be depressingly unsophisticated.sluggish in the presence of endogenous PrPC, sug-
Presymptomatic diagnosis is virtually impossible, andgesting that clonal deletion is actually occurring. B cell
the earliest possible diagnosis is based on clinical signsclones with the highest affinity to PrPC are probably
and symptoms. Hence, prion infection is typically diag-eliminated by tolerance, while clones with medium affin-
nosed after the disease has considerably progressed.ity are retained (Figure 5A). The latter sufficed to block
A significant advance in prion diagnostics was accom-prion pathogenesis upon intraperitoneal prion inocula-
plished in 1997 by the discovery that protease-resistanttion (Heppner et al., 2001). Hence, B cells are not intrinsi-
PrPSc can be detected in tonsillar tissue of vCJD patientscally tolerant to PrPC and can, in principle, mount a
(Hill et al., 1997b). It was hence proposed that tonsilprotective humoral response against prions. It was then
biopsy may be the method of choice for diagnosis offound, in a followup study, that passive transfer of anti-
vCJD (Hill et al., 1999). Furthermore, there have beenPrP monoclonal antibodies (in admittedly heroic amounts)
reports of individual cases showing detection of PrPSccan delay the onset of scrapie in mice infected with
at preclinical stages of the disease in tonsil (Schreuderprions intraperitoneally, albeit not such infected intrace-
et al., 1996) as well as in the appendix (Hilton et al., 1998),rebrally (White et al., 2003).
The challenges to a practical antiprion immunization, indicating that lymphoid tissue biopsy may be useful for
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Figure 5. Affinity of Antibodies, Tolerance,
and Immunity against Prions
(A) When forced to express a transgenic
heavy chain with anti-PrP specificity, B lym-
phocytes may couple it to a large repertoire of
endogenous light chains. Some of the VH-VL
pairs (variable domains of heavy and light
chains) may yield very high-affinity antibod-
ies, whereas others will have low or no affinity.
(B) Mendelian crosses of -PrP-VH trans-
genic mice with Prnpo/o, wild-type, and PrPC-
overexpressing transgenic mice informed on
tolerogenic constraints. In the absence of en-
dogenous PrPC, mouse sera exhibited high
anti-PrPC titers. In wild-type mice, anti-PrPC
titers despite some clonal deletion, whereas
massive overexpression of PrPC led to dra-
matic lymphopenia (Heppner et al., 2001). In-
stead, active immunization yields consis-
tently high anti-PrPC titers only in Prnpo/o mice.
The permissivity of B lymphocytes to expres-
sion of anti-PrPC specificities implies that tol-
erance to PrPC is predominantly dictated by
T-helper constraints. CH: Constant region of
the heavy chain. Fab: antigen binding frag-
ment. Fc: IgM-specific heavy chain.
diagnosing presymptomatic individuals. These observa- be a vCJD-specific feature that would not apply to any
other forms of human prion diseases (Hill et al., 1999).tions triggered large screenings of human populations
for subclinical vCJD prevalence using appendectomy However, a recent survey of peripheral tissues of pa-
tients with sporadic CJD has identified PrPSc in as manyand tonsillectomy specimens (Glatzel et al., 2003b).
PrPSc-positive lymphoid tissue was long considered to as one-third of skeletal muscle and spleen samples
Figure 6. A Model for the Antiprion Action of PrP-Fc2
The template refolding model of prion replication (top) postulates a transient dimerization of PrPC and PrPSc. As a result, PrPSc would impart
its own  sheet-rich, protease-resistant conformation onto PrPC. In the absence of PrPC, soluble dimeric PrP does not support replication of
the infectious agent, nor formation of a protease-resistant moiety (middle). Although several lines of evidence indicate that it can associate
with PrPSc, this association is nonproductive. Mice coexpressing PrPC and soluble dimeric PrP replicate prions and eventually develop scrapie.
However, the kinetics with which scrapie pathology develops, prion infectivity replicates, and PrPSc accumulates is slower than in wild-type
mice. All experimental evidence presented here suggests that PrP-Fc2 sequesters incoming as well as nascent PrPSc and renders it unavailable
for further template-directed conversion of PrPC (bottom).
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(Glatzel et al., 2003a), as well as the olfactory epithelium PrPC, into a likeness of itself? Which other proteins
assist this process? Can we inhibit this process? Ifof patients suffering from sCJD (Zanusso et al., 2003).
These unexpected findings raise the hope that minimally so, how?
• What is the essence of prion strains, which are opera-invasive diagnostic procedures may take the place of
brain biopsy in intravital CJD diagnostics. tionally defined as variants of the infectious agent
capable of retaining stable phenotypic traits upon se-The sensitivity of PrPSc detection was significantly
improved by the sodium phosphotungstic (NaPTA) pre- rial passage in syngeneic hosts? The existence of
strains is very well known in virology, but it was notcipitation method (Safar et al., 1998; Figure 1). By con-
centrating PrPSc prior to Western blot analysis, this pro- predicted to exist in the case of an agent that propa-
gates epigenetically.cedure improves the sensitivity of diagnostic assays by
as much as 4 orders of magnitude (Wadsworth et al., • How do prions reach the brain after having entered
the body? Which molecules and which cell types are2001). An interesting development was brought about
by the conformation-dependent immunoassay (CDI), in involved in this process of neuroinvasion? Which in-
hibitory strategies are likely to succeed?which conformational differences of PrP isoforms are
mapped by quantitating the relative binding of antibod- • The mechanisms of neurodegeneration in spongiform
encephalopathies is not understood. Which are theies to denatured and native protein (Safar et al., 1998).
Rather than relying on protease resistance, the CDI mea- pathogenetic cascades that are activated upon accu-
mulation of disease-associated prion protein and ulti-sures a variety of misfolded PrP isoforms, which may
increase its sensitivity (Bellon et al., 2003; Safar et al., mately lead to brain damage?
• What is the physiological function of the highly con-2002).
Be this as it may, all techniques described above served, normal prion protein, PrPC? The Prnp gene
encoding PrPC was identified in 1985 (Basler et al.,suffer from the fact that PrPSc continues to represent a
surrogate marker for prion infectivity—since (1) PrPSc 1986; Oesch et al., 1985), Prnp knockout mice were
described in 1992 (Bu¨eler et al., 1992), and some PrPC-has not been incontrovertibly shown to be congruent
with the prion, and (2) several manipulations in vitro interacting proteins have been identified (Oesch et al.,
1990; Rieger et al., 1997; Yehiely et al., 2002; Zanata etand in vivo can render PrPC protease resistant without
bestowing infectivity on it (Jackson et al., 1999). There- al., 2002). Yet the function of PrPC remains unknown!
fore, determination of prion infectivity by bioassay re-
The questions described above deserve to be addressedmains the golden standard; like in Pasteur’s age, the
with a vigorous research effort. Their study is likely toconcentration of the infectious agent is determined by
yield fundamental insights into the characteristics ofinoculating serial dilutions of the test material into exper-
these novel and essentially mysterious agents and mayimental animals, and the dilution at which 50% of the
yield useful leads for the diagnosis and therapy of prionanimals contract the disease (termed ID50) is determined.
diseases.Naturally, this system is riddled with inconveniences:
scores of animals need to be sacrificed, and the incuba-
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